Advanced searches left 3/3

Malignant Mesothelioma - PubMed

Summarized by Plex Scholar
Last Updated: 23 January 2023

* If you want to update the article please login/register

Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma.

Advanced mesotheliomas have recently been found to have improved overall survival, especially for patients responding to those therapies. We discovered that refractory patients were actively recruiting CD3+CD8+ cytotoxic T-cells in their tumors through CXCL9 tumor cell transplantation after treatment, which was unexpectedly. These patients nevertheless had high somatic copy number changes in their tumors, which were related to elevated blood and tumor levels of IL-6 and CXCL8. Those pro-inflammatory cytokines resulted in elevated tumor secretion of VEGF and tumor enrichment in regulatory T-cells.

Source link: https://doi.org/10.1158/2159-8290.CD-22-0886


Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.

Patients commonly present with abdominal pain, cramp, vomiting, and weight loss with or without an asbestos history. Prognosis is largely poor, with epithelioid subtype being the most effective one on TNM stage and histologic subtype. With progressive dyspnea, a 59-year-old male and a 79-year-old female have been shown. Patient 1's PET-CT revealed metastatic disease in the pleura and extensive peritoneal carcinomatosis. Both patients on both sides of the diaphragm, polyserositis, and FDG-avid lymph nodes in the peritoneum were found on PET-CT of patient 2 with FDG-avid lymph nodes. Patient 1 was treated with carboplatin and gemcitabine, and patient 2 was not eligible for systemic therapy. If ascites is present, a presentation with polyserositis in the absence of relevant asbestos exposure could indicate malignant peritoneal mesothelioma, and a rapid invasive diagnostic should be performed.

Source link: https://doi.org/10.1159/000526974


Case report: Rare intrapulmonary malignant mesothelioma complicated with myositis.

Malignant pleural mesothelioma is a rare benign disease. The patient presented with leg muscle weakness as the first sign and was diagnosed with intrapulmonary malignant mesothelioma complicated by cancer-associated myositis on the basis of medical, histological, immunohistochemical, and radiological findings.

Source link: https://doi.org/10.3389/fonc.2022.1074821


A Rare Case of Primary Malignant Pericardial Mesothelioma Diagnosed with Pericardiotomy.

Primary malignant pericardial mesothelioma is a rare and lethal cardiac tumor. This story is about a 62-year-old man with recurrent pericardial fluid. Pericardiotomy was attempted to diagnose and improve the patient's symptoms; however, the therapy was ineffective because the pericardium was densely adherent to the myocardium. We provided adjuvant therapy for the patient with cis-platinum and pexed, but the patient and his family refused to receive medication; however, the patient and his family refused to undergo treatment. The patient's symptoms improved, and the patient lived beyond the median survival after surgical therapy, according to this study. Conclusion: The definitive diagnosis of PMPM has been derived mostly from specimens obtained by surgery.

Source link: https://doi.org/10.1532/hsf.5047


Unprecedented long-term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo- and immunotherapeutic regimens.

Pleural mesothelioma is a rare disorder with a poor prognosis and no medical solutions. The median overall survival for a pleural mesothelioma patient was up to two years before recently, with few rare cases of patients surviving longer than others. In selected patients, a prolonged quality of life can be achieved through the exploitation of the available treatments in an expertise setting, as shown by our example.

Source link: https://doi.org/10.1111/1759-7714.14789


Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.

Malignant pleural mesothelioma is a malevolent tumor that arises from pleura and often leads to poor prognosis. In pan-cancer's first-line recommendation of MPM, dual immunotherapy has been extensively tested, and MPM's first-line advice of MPM has been widely tested, while MPM patients are only marginally benefit from the immune checkpoint inhibitor combination or monotherapy in second-line therapy.

Source link: https://doi.org/10.1097/MD.0000000000032459


Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.

Historically, malignant pleural mesothelioma is a common and rare malignant pleural tumor. Methods: The purpose of this investigation was to investigate MPM patients admitted in Beijing's Chaoyang Hospital and Beijing Tongren Hospital. Cox univariable and multivariable analyses were used at the same time to investigate the laboratory risk factors that influence MPM patients's prognosis. Results: In this study, 129 MPM patients were included in the study. The most useful mesothelial markers to support a MPM diagnosis were Calretinin, Wilms' tumor gene, cytokeratin 5/6, and D2-40. The MRI findings of MPM patients are pleural thickening and pleural effusion. Conclusions: The prognosis of MPM patients may be related to age, ESR, lymphocytes, platelets, and total protein.

Source link: https://doi.org/10.3390/medicina58121874

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions